abstract |
The present invention provides novel HMG-CoA reductase inhibitors. In a preferred embodiment, the HMG-CoA reductase inhibitor according to the present invention can be inactivated to primary inactive metabolites by hydrolyzing enzymes. The compounds according to the invention can advantageously be used for the treatment of patients suffering from hypercholesterolemia. |